This could be assessed using a modified IFA assay able to quantify GPC-1 fluorescent signal, and normalising to prostate cancer cell content using PSA expression (as is used for normalization in the PCA3 test [19]). This evidence concerns the gene GPC1 and prostate carcinoma.